Navigation Links
ADVENTRX Pharmaceuticals Announces Financing
Date:8/5/2009

of Delaware General Corporation Law will prohibit ADVENTRX from making the dividend and other payments due its 5% Series C convertible preferred stock (or to the holders thereof), which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability; the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to submit an NDA for ANX-530, to fund operations or pre-launch activities during the FDA review period if an NDA is submitted or launch activities should an NDA for ANX-530 be approved; the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to continue as a going concern; the risk that ADVENTRX will seek protection under the provisions of the U.S. Bankruptcy Code; the risk that, if ADVENTRX liquidates its assets, the capital available for distribution to stockholders, if any, will be insignificant; difficulties or delays in manufacturing, obtaining regulatory approval for and marketing ANX-530 and ANX-514, including validating commercial manufacturing processes and manufacturers, as well as suppliers, and the potential for automatic injunctions regarding FDA approval of ANX-514; the risk that the performance of third parties on whom ADVENTRX relies to conduct its studies or evaluate the data, including clinical investigators, expert data monitoring committees, contract laboratories and contract research organizations, may be substandard, or they may fail to perform as expected; the risk that ADVENTRX's significantly reduced workforce and leadership by officers who do not have substantial previous experience in executive leadership roles will negatively impact its ability to raise capital or maintain effective disclosure controls and procedures or internal control over financial reporting; the risk that ADVENTRX's common stock will be delisted by the NYSE Amex, including as a result of failing to maintain sufficient stock
'/>"/>
SOURCE ADVENTRX Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related biology technology :

1. ADVENTRX Pharmaceuticals Announces Plans for Remainder of 2009
2. ADVENTRX Pharmaceuticals Announces Closing of Financing
3. ADVENTRX Pharmaceuticals Announces Financing
4. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
5. ADVENTRX Announces Further Cost-Cutting Measures
6. ADVENTRX Provides Update on Strategic Transaction Process
7. ADVENTRX Announces Further Cost-Cutting Measures
8. ADVENTRX Exploring Strategic Options
9. ADVENTRX Pharmaceuticals Reports Third Quarter 2008 Financial Results and Business Update
10. ADVENTRX Pharmaceuticals to Present at the Rodman & Renshaw 10th Annual Global Healthcare Conference
11. ADVENTRX Announces Restructuring and Cost Reduction Initiatives
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/26/2015)... , Aug. 26, 2015 /PRNewswire/ - iCo Therapeutics ("iCo" ... reported financial results for the quarter ended June ... in Canadian dollars and presented under International Financial ... activities with respect to our Oral Amp B ... contract manufacturer," said Andrew Rae , President ...
(Date:8/26/2015)... , Aug. 26, 2015  Platform therapeutic company ... has received a $1.5M Phase II SBIR grant ... further develop its therapeutic agent to reduce arteriovenous ... in end stage renal disease (ESRD) patients undergoing ... Institute of Diabetes and Digestive and Kidney Diseases ...
(Date:8/26/2015)... 2015 After litigating and negotiating patent ... to P2i United States patent RE43,651 ... the United States without any admission ... either party. As a result of the parties, settlement, the ... California dismissed the case without prejudice. ...
(Date:8/25/2015)... , Aug. 25, 2015   WuXi PharmaTech (Cayman) ... capability and technology platform company serving the pharmaceutical, biotechnology, ... ("Lee,s Pharm," Hong Kong Exchange Stock Code: 0950), a ... with 20 years of operations in ... companies have signed an agreement whereby WuXi,s Laboratory Testing ...
Breaking Biology Technology:iCo Therapeutics Announces Second Quarter 2015 Financial Results 2iCo Therapeutics Announces Second Quarter 2015 Financial Results 3Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 2Symic Biomedical Awarded $1.5MM NIH Phase II SBIR Grant to Develop its Proteoglycan Mimetic Therapeutics to Reduce Vascular Access Failures in ESRD 3P2i Settles United States Litigation 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 2WuXi PharmaTech to Be Exclusive Supplier of Laboratory Testing Services to Lee's Pharm 3
... QC, May 19 /PRNewswire-FirstCall/ - Neptune Technologies & ... its consolidated financial results for the fiscal year ... EBITDA(1) and first-time profitability for the three-month period ... amended their stock option plan. , Neptune reports ...
... Reprints NRx for the Force.com AppExchange saves time for ... process from within Salesforce CRMSANTA MONICA, Calif., May 19 ... announced the availability of Reprints NRx for ... the Force.com platform, Reprints NRx for the AppExchange is ...
... Cell Therapeutics, Inc. (the "Company" or "CTI") (Nasdaq and MTA: ... Auction" tender offer (the "Exchange Offer") to increase the total ... stock, no par value (the "Common Stock"), and cash for ... the following outstanding series of its convertible notes (the "Notes"):, ...
Cached Biology Technology:Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 2Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 3Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 4Neptune Technologies Reports Fiscal 2009 Results - Record revenue and profitability growth in nutraceutical business 5Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 2Reprints Desk Medical Reprint Service Now Available to Life Science Professionals on the Force.com AppExchange 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 2Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 3Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 4Cell Therapeutics Amends 'Modified Dutch Auction' Tender Offer for up to $89.2 million of Its Outstanding Convertible Notes 5
(Date:8/18/2015)... 18, 2015  Navitas today announced that ... the Submission Content Management webinar scheduled on ... forum. Dedicated to the Implementation of Regulatory Submission ... for industry, vendors, health authorities, consultants and ... towards a standard method of implementing electronic ...
(Date:8/17/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market and creator of the ... Q4 2015. The new marketing campaign is being spearheaded ... Marketing Group ( http://amplitudemarketing.com/ ) and TPMG ( http://tmpg.com/ ... in retail driven marketing and brand awareness and has ...
(Date:8/12/2015)... , August 12, 2015 ... of mobile payment innovation and advanced biometrics technology is ... the way consumers rely on using their credit cards, ... reinventing the future for payment services led by companies ... NXTD ), :  Google, Inc. (NASDAQ: GOOG ), ...
Breaking Biology News(10 mins):Navitas, a Key Contributor in IRISS Forum Webinar 2Navitas, a Key Contributor in IRISS Forum Webinar 3NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 2NXT-ID, Inc. Launches Sales Campaign for Wocket Smart Wallet with Award Winning Marketing Team 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 2Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 3Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 4Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 5Digital Wallet Devices & Mobile Payment Management Services Gain a Distinct Advantage in the Digital Payment Evolution as Demand Continues to Grow 6
... demonstrated that morphine withdrawal complicates hepatitis C by suppressing ... Wang et al., Morphine withdrawal enhances hepatitis C virus ... The American Journal of Pathology and is accompanied by ... is common among intravenous drug users, with 70 to ...
... can result in two immune system disorders that ... severe infections, according to new findings reported in ... may lead to new diagnostic tests for these ... common variable immunodeficiency (CVID). Currently, doctors diagnose the ...
... a "time machine," assert Duke neuroscientists Catalin Buhusi and ... is essential to understanding all its functions. The brain's ... communicating, to orchestrating movement, to getting food, they said. ... Nature Reviews Neuroscience, Buhusi and Meck discuss the current ...
Cached Biology News:Hepatitis C complicated by morphine withdrawal 2Biologists Crack Genetic Code for Specialized Spider Silk 2Biologists Crack Genetic Code for Specialized Spider Silk 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 2What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 3What Makes The Brain Tick, Tick, Tick: Researchers Gaining New Insights Into Brain's Internal Clock 4
... system uses the Adept CE 4100 high pressure ... UV/Visible detector for added flexibility and utra low ... alternative to a photodiode array detection and provides ... is required for method development and for monitoring ...
... is a new product number, created ... If showing no availability yet, please ... (E6152) or contact customer service for ... diam. 11.25 6.40 in. ...
... numbers of samples may be carried out using ... attention. System control and data processing is ... The elegant, powerful and very easy to ... 98 and 2000., The supplied detector is the ...
Mouse monoclonal antibody to QPCT - glutaminyl-peptide cyclotransferase (glutaminyl cyclase)...
Biology Products: